Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) Invested Capital: 2009-2024

Historic Invested Capital for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $154.0 million.

  • Anika Therapeutics' Invested Capital fell 18.38% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.8 million, marking a year-over-year decrease of 18.38%. This contributed to the annual value of $154.0 million for FY2024, which is 27.45% down from last year.
  • Per Anika Therapeutics' latest filing, its Invested Capital stood at $154.0 million for FY2024, which was down 27.45% from $212.3 million recorded in FY2023.
  • Anika Therapeutics' Invested Capital's 5-year high stood at $291.4 million during FY2021, with a 5-year trough of $154.0 million in FY2024.
  • For the 3-year period, Anika Therapeutics' Invested Capital averaged around $217.3 million, with its median value being $212.3 million (2023).
  • Its Invested Capital has fluctuated over the past 5 years, first grew by 2.07% in 2021, then declined by 27.45% in 2024.
  • Yearly analysis of 5 years shows Anika Therapeutics' Invested Capital stood at $285.5 million in 2020, then rose by 2.07% to $291.4 million in 2021, then dropped by 2.00% to $285.6 million in 2022, then dropped by 25.67% to $212.3 million in 2023, then dropped by 27.45% to $154.0 million in 2024.